Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With WHO or ISN Class III or IV Nephritis Due to Systemic Lupus Erythematosus

NCT00626197 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00626197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00626197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With WHO or ISN Class III or IV Nephritis Due to Systemic Lupus Erythematosus
Lead sponsor
Genentech, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
February 15, 2008
Completion date
October 28, 2013
Enrollment
381 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lupus nephritis, systemic lupus erythematosus